In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3- sulfate and trans-resveratrol-3-glucuronide

Satish Sharan, Otito F. Iwuchukwu, Daniel J. Canney, Cheryl L. Zimmerman, Swati Nagar

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Metabolites in safety testing have gained a lot of attention recently. Regulatory agencies have suggested that the kinetics of preformed and in vivo-formed metabolites are comparable. This subject has been a topic of debate. We have compared the kinetics of in vivo-formed with preformed metabolites. trans-3,5,4′-Trihydroxystilbene [trans-resveratrol (RES)] and its two major metabolites, resveratrol-3-sulfate (R3S) and resveratrol-3-glucuronide (R3G) were used as model substrates. The pharmacokinetics (PK) of R3S and R3G were characterized under two situations. First, the pharmacokinetics of R3S and R3G were characterized (in vivo-formed metabolite) after administration of RES. Then, synthetic R3S and R3G were administered (preformed metabolite) and their pharmacokinetics were characterized. PK models were developed to describe the data. A three-compartment model for RES, a two-compartment model for R3S (preformed), and an enterohepatic cycling model for R3G (preformed) was found to describe the data well. These three models were further combined to build a comprehensive PK model, which was used to perform simulations to predict in vivo-formed metabolite kinetics. Comparisons were made between in vivo-formed and preformed metabolite kinetics. Marked differences were observed in the kinetics of preformed and in vivo-formed metabolites.

Original languageEnglish (US)
Pages (from-to)1993-2015
Number of pages23
JournalDrug Metabolism and Disposition
Volume40
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Dive into the research topics of 'In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3- sulfate and trans-resveratrol-3-glucuronide'. Together they form a unique fingerprint.

Cite this